Introduction
The overall risk of chromosomal abnormalities in twin pregnancies is increased, both because two fetuses are involved and because twin pregnancies are frequently associated with advanced maternal age.
However, the incidence and probability of chromosomal abnormalities differ between the various types of twin pregnancies, depending on how they originate.
More specifically:
– Dichorionic diamniotic (DCDA) twins, the majority of which are dizygotic (90%), result from the fertilization of two separate oocytes. Consequently, each fetus has an independent risk of chromosomal abnormalities, and the overall pregnancy-related risk is theoretically twice the maternal age-related risk for a singleton pregnancy. Nevertheless, the probability of both fetuses being affected by a chromosomal abnormality is relatively low.
– In contrast, monochorionic diamniotic (MCDA) twin pregnancies result from the fertilization of a single oocyte followed by division of the developing embryo. Consequently, the two fetuses share the same genetic material and theoretically have a lower overall risk of chromosomal abnormalities than dichorionic twins, comparable to the maternal age-related risk in singleton pregnancies. Rare cases of genetic discordance between monochorionic twins have been reported. In practice, trisomy 21 is approximately three times less common in MCDA twin pregnancies than in singleton pregnancies, possibly because the probability of both affected fetuses surviving is relatively low
Screening for Chromosomal Abnormalities
As in singleton pregnancies, first-trimester ultrasound examination is the preferred first choise screening method.
Furthermore, this examination is useful for determining the zygosity of the pregnancy, the number of amniotic sacs, and the twin labeling, allowing consistent identification during subsequent examinations.
When gestational age is uncertain, it is determined using the crown–rump length (CRL) of the larger fetus. When the date of conception is precisely known, as in assisted reproduction, this information can be used for pregnancy dating.
The use of the combined first-trimester screening test, which incorporates maternal age, nuchal translucency (NT) measurement, and maternal serum biochemical markers, allows the detection of approximately 90% of chromosomal abnormalities in twin pregnancies, with a screen-positive rate of approximately 6–9%, compared with 5% in singleton pregnancies.
The difference in screening performance is partly attributable to the fact that increased nuchal translucency in monochorionic pregnancies (9%) may reflect the early development of twin-to-twin transfusion syndrome (TTTS), rather than necessarily indicating a chromosomal abnormality.
According to some studies, in MCDA pregnancies, an intertwin nuchal translucency discordance exceeding 20%, observed in approximately 25% of cases, is associated with an increased subsequent risk of TTTS and a higher probability of spontaneous loss of one of the twins (30%).
In dichorionic pregnancies, the separate assessment of nuchal translucency in each fetus has diagnostic value. However, this approach is less applicable to monochorionic twins because both fetuses generally share the same genetic material and are therefore expected to have a similar risk of chromosomal abnormalities
However, in dichorionic twin pregnancies, the contribution of each fetus to the overall maternal serum biochemical marker concentrations cannot be determined individually.
Consequently, biochemical markers originating from the unaffected pregnancy may mask those associated with the affected fetus, making it difficult to obtain an accurate individual risk assessment for each twin.
Therefore, the use of maternal serum biochemical markers is theoretically more reliable in monochorionic twin pregnancies.
Non-Invasive Prenatal Testing (NIPT)
Non-Invasive Prenatal Testing (NIPT) has demonstrated high detection rates in singleton pregnancies:
Trisomy 21 (T21): 99.7% detection rate, with a false-positive rate of 0.04%.
Trisomy 18 (T18): 97.9% detection rate, with a false-positive rate of 0.04%.
Trisomy 13 (T13): 99% detection rate, with a false-positive rate of 0.04%.
Nevertheless, NIPT may occasionally fail to provide a result because of an insufficient fetal fraction, meaning that the proportion of fetal cell-free DNA in the maternal circulation is too low for reliable analysis.
Factors associated with a low fetal fraction include advanced maternal age, early gestational age, increased maternal body weight, conception through in vitro fertilization (IVF), and dichorionic twin pregnancies.
In dichorionic pregnancies, the contribution of each fetus to the total fetal cell-free DNA may differ substantially, with one fetus contributing up to twice as much DNA as the other.
Consequently, the DNA originating from one fetus may predominate over that of the other. If the fetus contributing the smaller proportion of DNA carries a chromosomal abnormality, its abnormal genetic signal may be masked, potentially resulting in a falsely normal result for the pregnancy rather than identifying one unaffected and one affected fetus.
In contrast, in monochorionic twin pregnancies, the fetal fraction is considered a combined contribution from genetically identical fetuses, and the performance of NIPT is therefore comparable to that observed in singleton pregnancies.
These factors should be taken into consideration when counseling parents about the interpretation and limitations of NIPT results.
When no result is obtained because of an insufficient fetal fraction, repeating NIPT at a later gestational age is recommended, as the fetal fraction generally increases as pregnancy progresses.
Another important factor is the contribution of cell-free DNA from a fetus that has undergone spontaneous demise, a phenomenon known as a vanishing twin.
This may lead to unreliable NIPT results because cell-free DNA originating from the demised fetus can continue to influence the total fetal fraction until approximately the 15th week of gestation.
In conclusion, NIPT demonstrates high screening performance in twin pregnancies, particularly for trisomy 21:
Chromosomal abnormality | Detection rate | False-positive rate |
|---|---|---|
Trisomy 21 (T21) | 99% | 0.02% |
Trisomy 18 (T18) | 93% | 0.01% |
Trisomy 13 (T13) | 95% | 0.10% |
For this reason, NIPT should be accompanied by first-trimester combined screening, including nuchal translucency assessment and maternal serum biochemical markers.
Diagnosis
Invasive prenatal diagnostic procedures, including chorionic villus sampling (CVS) and amniocentesis, remain the methods of choice for the definitive diagnosis of fetal chromosomal abnormalities.
However, fetal loss rates involving both twins have been reported as 3.84% following chorionic villus sampling and 3.04% following amniocentesis.
Therefore, these procedures should be performed only when clearly indicated and by experienced specialists